Repetitive transcranial photobiomodulation but not long‐term omega‐3 intake reduces epileptiform discharges in rats with stroke‐induced epilepsy

Vogel, Debora; Ortiz‐Villatoro, Nancy N.; Freitas, Leandro; Aimbire, Flávio; Scorza, Fúlvio A.; Albertini, Regiane; Scorza, Carla A.

doi:10.1002/jbio.202000287

Cited by 16 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, PBM reduced the apoptotic ratio of parvalbumin-labeled interneurons and alleviated the aberrant extent of parvalbumin-labeled unstained somata of principal cells in the hippocampus. Second, Vogel et al ( 29 ) observed that PBM reduces epileptiform discharges after a stroke ( 29 ). They showed that a 780 nm wavelength laser treatment for 2 months after induction of photothrombotic stroke reduced late epileptic electrographic seizures, as well as the number of spikes in the ipsilateral and contralateral cortices and in the ventral posteromedial thalamic nuclei.…”

Section: Studies Of Photobiomodulation In Epilepsy Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Mitochondrial Photobiomodulation as a Neurotherapeutic Strategy for Epilepsy

2022

View full text Add to dashboard Cite

Section: Studies Of Photobiomodulation In Epilepsy Modelsmentioning

confidence: 99%

“…Although these studies present interesting behavioral findings on PBM in epilepsy ( 28 , 29 ), evidence regarding mitochondrial functions is still lacking. This line of reasoning would be interesting since studies show that mitochondrial damage under various conditions is restored by PBM.…”

Section: Studies Of Photobiomodulation In Epilepsy Modelsmentioning

confidence: 99%

Mitochondrial Photobiomodulation as a Neurotherapeutic Strategy for Epilepsy

2022

View full text Add to dashboard Cite

“… 7 Vogel et al. 8 further revealed that repetitive tPBM (780 nm) reduced epileptiform discharges in a rat model of stroke-induced epilepsy. Regarding neuroprotection, tPBM has shown effects in reducing neuroinflammatory cytokines, 7 , 9 which along with neuron-specific enolase (NSE) increased in the hippocampus after convulsive status epilepticus (CSE).…”

Section: Introductionmentioning

confidence: 96%

Transcranial photobiomodulation (808 nm) attenuates pentylenetetrazole-induced seizures by suppressing hippocampal neuroinflammation, astrogliosis, and microgliosis in peripubertal rats

Tsai

Chang

et al. 2022

Neurophoton.

View full text Add to dashboard Cite

. Significance: Transcranial photobiomodulation (tPBM) at 808 nm attenuates pentylenetetrazole (PTZ)-induced seizures and convulsive status epilepticus (CSE) in peripubertal rats by protecting neurons from injury and parvalbumin-positive interneurons from apoptosis, and preserving the integrity of perisomatic inhibitory networks. However, the effects of tPBM on neuroinflammation, astrogliosis, and microgliosis in epileptic rat brains are unknown. Thus, further study to unveil these aspects is needed for understanding the phenomena of tPBM on pediatric CSE prevention. Aim: To evaluate the effects of tPBM on neuroinflammation, astrogliosis, and microgliosis in peripubertal rat hippocampus with PTZ-induced seizures and SE. Approach: An 808-nm diode laser was applied transcranially to peripubertal rats prior to PTZ injection. Immunofluorescence staining of neuron-specific enolase (NSE) was used as a marker of neuroinflammation, glial fibrillary acid protein (GFAP) for astrogliosis, ionized calcium-binding adapter molecule 1 (Iba-1) for microgliosis, and mitochondrial cytochrome c oxidase subunit 1 (MT-CO1) for confirming the involvement of cytochrome c oxidase (CCO). Results: tPBM significantly reduced NSE immunoreactivity in CA3 in PTZ-treated rats, GFAP immunoreactivity in CA1, and Iba-1 immunoreactivity in CA3. Enhancement of hippocampal MT-CO1 reflected that tPBM acted in CCO-dependent manner. Conclusions: tPBM (808) attenuated PTZ-induced seizures and SE by suppressing neuroinflammation, astrogliosis, and microgliosis in peripubertal rats.

show abstract

“…Transcranial photobiomodulation (tPBM) is the application of PBM transcranially and noninvasively. tPBM has been applied to dementia including Alzheimer's disease, 23 traumatic brain injury, 24 stroke, 25 epilepsy, 17,21,26,27 PTSD, 28 anxiety and depression. 29 Corresponding to the two main mechanisms (α-synnuclein aggregation and mitochondrial dysfunction or failure of mitochondrial biogenesis) and a potential therapeutic target (microglial activation) in the pathogenesis of PD, PBM has correlated therapeutic effects against them respectively.…”

Section: Introductionmentioning

confidence: 99%

Progress of Photobiomodulation for Parkinson’s Disease

Tsai¹

2022

SOJCEM

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative disease with global burden. The mechanisms and therapeutic effects of photobiomodulation (PBM) correspond to main mechanisms in the pathogenesis of PD. Numerous research results applying PBM for PD were published during the past two decades. Although several systematic review or review articles provided complete introduction, they are either mainly basic research or clinical research, and the year of the article publication is up to 2020. Comprehensive systematic review or review articles containing basic and clinical studies including those published articles is lacking. Hence, this systematic review aimed to include both basic and clinical studies published up to 2022. Results were obtained by retrieving articles from PubMed with the intersection of the articles derived from the terms of PBM synonyms and Parkinson’s disease followed by exclusion. Sixty-nine articles were included ultimately. Among them, 40 original articles were identified, which were composed of 31 basic research and 9 original articles of clinical research. Twenty-one review articles, a systematic review with focused content on PD, and 7 review articles with the term PD under general illustration of PBM were presented. Mechanisms regarding the therapeutic effects of PBM on the vitro studies were reviewed. Positive outcomes on motor symptoms after PBM treatments were shown in most in vivo and clinical studies. The immunohistochemical examination of in vivo studies reflect the therapeutic effects of PBM on the preservation even reverse of the pathogenic insults of PD on the in vitro studies. The most frequently used wavelength among original articles included was 670nm. Considering the acceptability of PBM for patients with PD, noninvasive transcranial PBM (tPBM) had crucial roles in respect to invasive intracerebral PBM. To match the penetration depth reaching deep brain target, Substantia nigra pars compacta, in human brains of patients with PD, the wavelength 810nm might match the need in the clinical setting of tPBM. More future clinical studies were needed. In conclusion, therapeutic approaches applying PBM for PD are promising. Recent studies revealed positive outcomes. Future clinical practices containing PBM are to be expected.

show abstract

Repetitive transcranial photobiomodulation but not long‐term omega‐3 intake reduces epileptiform discharges in rats with stroke‐induced epilepsy

Abstract: Epilepsy is a yet under-recognized consequence after a stroke and nearly 30% of cases are pharmacoresistant. There is an unmet need for therapeutic interventions during epileptogenesis for better long-term disease outcomes. Transcranial photo

Cited by 16 publications

References 14 publications

Mitochondrial Photobiomodulation as a Neurotherapeutic Strategy for Epilepsy

Mitochondrial Photobiomodulation as a Neurotherapeutic Strategy for Epilepsy

Transcranial photobiomodulation (808 nm) attenuates pentylenetetrazole-induced seizures by suppressing hippocampal neuroinflammation, astrogliosis, and microgliosis in peripubertal rats

Progress of Photobiomodulation for Parkinson’s Disease

Contact Info

Product

Resources

About